Crenolanib CAS: 670220-88-9
MF: C26H29N5O2
MW: 443.54
A selective inihibitor of PDGFRα.

Crenolanib (CAS 670220-88-9)

Crenolanib | CAS 670220-88-9 is rated 5.0 out of 5 by 1.
  • y_2022, m_5, d_20, h_22
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.27
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_364470, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 167ms
  • REVIEWS, PRODUCT
loading
5
1
4
0
3
0
2
0
1
0
Alternate Names: CP-868596
Application: Crenolanib is a selective inihibitor of PDGFRα
CAS Number: 670220-88-9
Purity: ≥98%
Molecular Weight: 443.54
Molecular Formula: C26H29N5O2
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data (including water content).
loading

Crenolanib (CP-868569) is a potent, oral, selective inihibitor of PDGFRα, with IC50 with 10 nM in PDGFRα over-expressed CHO cells.

Appearance :
Powder
Physical State :
Solid
Solubility :
Soluble in DMSO (89 mg/ml at 25 °C), water (<1 mg/ml at 25 °C), and ethanol (7 mg/ml at 25 °C).
Storage :
Store at -20° C
Melting Point :
283.14° C (Predicted)
Boiling Point :
~676.6° C at 760 mmHg (Predicted)
Density :
~1.4 g/cm3 (Predicted)
Refractive Index :
n20D 1.70 (Predicted)
IC50 :
PDGFRα: IC50 = 2.1 nM; PDGFRβ: IC50 = 3.2 nM
pK Values :
pKb: 9.84 (Predicted)
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
PubChem CID :
MDL Number :
MFCD21609260
SMILES :
CC1(COC1)COC2=CC3=C(C=C2)N(C=N3)C4=NC5=C(C=CC=C5N6CCC(CC6)N)C=C4

Download SDS (MSDS)

Certificate of Analysis

Adobe Acrobat Reader is required to reliably view,
print and comment on PDF documents

  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 100ms
  • QUESTIONS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
Rated 5 out of 5 by from Hayahsi et al Hayahsi et al. (PubMed ID 25865047) used Crenolanib to inhibit PDGFRA in human GIST cells with imatinib-resistant or imatinib-sensitive mutations. -SCBT Publication Review
Date published: 2015-03-22
  • y_2022, m_5, d_20, h_22
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.27
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_364470, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 14ms
  • REVIEWS, PRODUCT